AAAAAA

   
Results: 1-11 |
Results: 11
Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility
Authors: Lievre, M Menard, J Bruckert, E Cogneau, J Delahaye, F Giral, P Leitersdorf, E Luc, G Masana, L Moulin, P Passa, P Pouchain, D Siest, G
Citation: M. Lievre et al., Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility, BR MED J, 322(7286), 2001, pp. 603-605
The AFSSAPS recommendations for good practice: Therapeutic management of patients with dyslipidemia.
Authors: Ducimetiere, P Signeyrole, D Giral, P Hoog-Labouret, N Amarenco, P Chanu, B Chauvenet, M Coletti, M Dallongeville, J Durlach, V Kawka, G Krempf, M Leroux, G Mlika-Cabanne, N Monnier, L Paillard, F Rostoker, G Sicard, D Verny, C Voiriot, P Acquart, B Alquier, G Ankri, J Badoc, G Basdevant, A Belmin, J Berthezene, F Beucler, I Blanc, F Broustet, JP Bruckert, E Brun, JM Castaigne, A Charpentier, JM Andre, MC Cogneau, J Demeaux, JL Denolle, T Desson, JF Drahi, E Drouin, P Dumel, F Emmerich, J Farnier, M Fontbonne, A Forette, B Gambert, P Gautier, JC Guillausseau, PJ Hommel, M Janowski, M Le Goaziou, MF Lievre, M Le Quere, M Leys, D Marechaud, R Mas, JL Menard, J Michel, JM Mounier-Vehier, F Mottier, D Passa, P Pinel, JF Puel, J Raccah, D Renou, P Ribier, A Schlienger, JL Thomas, D Vallee, JP Veyssier-Belot, C Bouvenot, G Abadie, E Alexandre, JM Belorgey-Bismut, C Bergmann, JF Camelli, B Caulin, C Costagliola, D Denis, C Dupuis, B Fleurette, F Guillevin, L Hoog-Labouret, N Paintaud, G Rauss, A Poynard, T Rostoker, G Wong, O
Citation: P. Ducimetiere et al., The AFSSAPS recommendations for good practice: Therapeutic management of patients with dyslipidemia., J MAL VASC, 26(2), 2001, pp. 105-110
Clinical benefit of cholesterol-lowering treatments - Reply
Authors: Cucherat, M Lievre, M Gueyffier, F
Citation: M. Cucherat et al., Clinical benefit of cholesterol-lowering treatments - Reply, PRESSE MED, 29(33), 2000, pp. 1827-1827
Clinical benefit of cholesterol lowering treatments: meta-analysis of randomized therapeutic trials
Authors: Cucherat, M Lievre, M Gueyffier, F
Citation: M. Cucherat et al., Clinical benefit of cholesterol lowering treatments: meta-analysis of randomized therapeutic trials, PRESSE MED, 29(17), 2000, pp. 965-976
In vivo measurement of myocardial oxidative metabolism and blood flow doesnot show changes in cancer patients undergoing doxorubicin therapy
Authors: Nony, P Guastalla, JP Rebattu, P Landais, P Lievre, M Bontemps, L Itti, P Beaune, J Andre-Fouet, X Janier, M
Citation: P. Nony et al., In vivo measurement of myocardial oxidative metabolism and blood flow doesnot show changes in cancer patients undergoing doxorubicin therapy, CANC CHEMOT, 45(5), 2000, pp. 375-380
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and Ramipril (DIABHYCAR) study: Design, organization, and patient recruitment
Authors: Lievre, M Marre, M Chatellier, G Plouin, PF Reglier, JC Richardson, L Bugnard, F Vasmant, D
Citation: M. Lievre et al., The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and Ramipril (DIABHYCAR) study: Design, organization, and patient recruitment, CONTR CL TR, 21(4), 2000, pp. 383-396
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa
Authors: Marre, M Lievre, M Vasmant, D Gallois, Y Hadjadj, S Reglier, JC Chatellier, G Mann, J Viberti, GC Passa, P
Citation: M. Marre et al., Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa, DIABET CARE, 23, 2000, pp. B40-B48
Efficacy of diuretics and beta-blockers in diabetic hypertensive patients - Results from a meta-analysis
Authors: Lievre, M Gueyffier, F Ekbom, T Fagard, R Cutler, J Schron, E Marre, M Boissel, JP
Citation: M. Lievre et al., Efficacy of diuretics and beta-blockers in diabetic hypertensive patients - Results from a meta-analysis, DIABET CARE, 23, 2000, pp. B65-B71
Oral beraprost sodium, a prostaglandin I-2 analogue, for intermittent claudication - A double-blind, randomized, multicenter controlled trial
Authors: Lievre, M Morand, S Besse, B Fiessinger, JN Boissel, JP
Citation: M. Lievre et al., Oral beraprost sodium, a prostaglandin I-2 analogue, for intermittent claudication - A double-blind, randomized, multicenter controlled trial, CIRCULATION, 102(4), 2000, pp. 426-431
Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention
Authors: Lantelme, P Bouchayer, D Gayet, C Lievre, M Gessek, J Milon, H
Citation: P. Lantelme et al., Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention, J HYPERTENS, 17(9), 1999, pp. 1323-1328
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients
Authors: Lievre, M Marre, M
Citation: M. Lievre et M. Marre, Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients, DIABET CARE, 22(1), 1999, pp. 178-179
Risultati: 1-11 |